Cynata Therapeutics has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute graft-versus-host disease (GvHD). The biotech company reported it had achieved a world first with the trial completion.
Cynata Therapeutics’ market-disruptive regenerative medicines complete world-first trial
Quick facts: Cynata Therapeutics Ltd
Market Cap: $164.02 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE